ResMed Inc. RMD
NYSE · Healthcare · Medical - Instruments & Supplies
$235.63
Close on Fri, 20 Nov 2026 · market value $33.1B
What the price is betting on
Below its recordAt $236, the price assumes revenue grows about 4.1% a year for five years, from $5.7B to about $7B by FY2031. That is about the same as what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 8.2% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than RMD? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$224
Base
$252
Bull
$284
Today $236
- Bear $224. Cash flow grows 3% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $252. Cash flow grows 5% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $284. Cash flow grows 8% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2027$5.9B$5.8B, on the path
- FY2028$6.2B$6.2B, on the path
- FY2029$6.4B$6.6B, on the path
- FY2030$6.7B$7.1B, on the path
- FY2031$7BThe full bet
Each year's revenue at 4.1% growth from $5.7B in the 12 months to September 2026.
At a glance
Healthcare · Medical - Instruments & Supplies · listed on NYSE
- Revenue, FY2026
- $5.7B
- Growth, 3 years a year
- 9.9%
- Cash margin
- 29%
- Net cash
- $643M
- Shares, 3-year change
- −1%
- Dividend yield
- 1.1%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.